Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 47
This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2017

Summary

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2017, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II and Preclinical stages are 2 and 4 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Ophthalmology which include indications Amyotrophic Lateral Sclerosis, Parkinson's Disease, Brain Ischemia, Neurodegenerative Diseases and Retinal Degeneration.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview 6
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development 20
GlaxoSmithKline Plc 20
Treeway BV 20
UniQure NV 20
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles 22
AMT-090 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Drugs for Neurodegenerative Diseases - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
GSK-812 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LAUR-301 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
smilagenin - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TW-002 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products 34
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones 35
Featured News & Press Releases 35
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients 35
Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association 36
Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy 37
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 37
Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane 38
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 39
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease 40
Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 40
Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 41
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 42
Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 43
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 43
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 44
Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson's Disease 44
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by GlaxoSmithKline Plc, H2 2017 20
Pipeline by Treeway BV, H2 2017 20
Pipeline by UniQure NV, H2 2017 21
Dormant Projects, H2 2017 34

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18
  • Cell Counting Market by Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023
    Published: 19-Jul-2018        Price: US 5650 Onwards        Pages: 242
    “The global cell counting market is projected to grow at a CAGR of 6.8%.” The cell counting market is expected to reach USD 12.32billion by 2023 from an estimated USD 8.84 billion in 2018, at a CAGR of 6.8%.Growing incidence of diseases and disorders, development of enhanced solutions and improved image analysis, and growing use of high-throughput flow cytometry and automated hematology analyzers are some of the factors driving the growth of this market. H......
  • Global Bioanalytical Testing Services Market Size, Status and Forecast 2025
    Published: 19-Jul-2018        Price: US 3300 Onwards        Pages: 91
    This report studies the global Bioanalytical Testing Services market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Bioanalytical Testing Services market by companies, region, type and end-use industry. In 2017, the global Bioanalytical Testing Services market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. This report f......
  • Global Organs-on-chips Market Research Report 2018
    Published: 18-Jul-2018        Price: US 2900 Onwards        Pages: 98
    This report studies the global Organs-on-chips market status and forecast, categorizes the global Organs-on-chips market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in United States, Europe, China, Japan, South Korea and Taiwan and other regions. The global Organs-on-chips market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. ......
  • 2018-2023 Global DNA Forensic Consumption Market Report
    Published: 17-Jul-2018        Price: US 4660 Onwards        Pages: 165
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global DNA Forensic market for 2018-2023. DNA forensics is a branch of forensic science that focuses on the use of genetic material in criminal investigation to answer questions pertaining to legal situations, including criminal and civil cases. The DNA forensics market will continue to be led by the sectors with applications in legal, law enforcement and ......
  • 2018 Top 5 DNA Forensic Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 17-Jul-2018        Price: US 4960 Onwards        Pages: 142
    DNA forensics is a branch of forensic science that focuses on the use of genetic material in criminal investigation to answer questions pertaining to legal situations, including criminal and civil cases. The DNA forensics market will continue to be led by the sectors with applications in legal, law enforcement and biodefense environments. Gradually, the balance should shift; as therapeutics derived from forensics origins or incorporated into pharmacogenomic medicines assert a more domina......
  • Global Human Microbiome Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 145
    The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bact......
  • Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023
    Published: 16-Jul-2018        Price: US 5650 Onwards        Pages: 135
    “The peptide synthesis market is projected to grow at a CAGR of 6.5% in the next five years” The peptide synthesis market is projected to reach USD 426.4million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. Factors such as increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to dri......
  • Global Antibody Services Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 16-Jul-2018        Price: US 3480 Onwards        Pages: 147
    Antibody services include competitively priced packages and purification options for antibody production. Service Providers offer support for different types and steps of antibody production—from peptide design, synthesis, and carrier protein conjugation to animal immunization, serum collection, or hybridoma fusion, titer analysis, and final antibody purification. They also immunize with recombinant proteins or protein fragments provided by the customers(or expressed and purified in labs using c......
  • Global and United States Microfluidics Market Research by Company, Type & Application 2013-2025
    Published: 14-Jul-2018        Price: US 2000 Onwards        Pages: 124
    Summary Market Segment as follows: By Type - Polymer-Based Microfluidics - Glass-Based Microfluidics - Silicon-Based Microfluidics - Other Materials-Based (Paper & Ceramics) Microfluidics By Application - Pharmaceutical Research - In Vitro Diagnostics - Drug Delivery By Company - Perkinelmer, Inc. - Cepheid, Inc. - Abbott Laboratories, Inc. - Thermo Fisher Scientific, Inc. - Agilent Te......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs